Thijssen, Elisabeth H.
,
La Joie, Renaud http://orcid.org/0000-0003-2581-8100
Wolf, Amy
Strom, Amelia
Wang, Ping
Iaccarino, Leonardo
Bourakova, Viktoriya
Cobigo, Yann
Heuer, Hilary
Spina, Salvatore
VandeVrede, Lawren http://orcid.org/0000-0002-8304-6711
Chai, Xiyun
Proctor, Nicholas K.
Airey, David C.
Shcherbinin, Sergey
Duggan Evans, Cynthia
Sims, John R.
Zetterberg, Henrik
Blennow, Kaj
Karydas, Anna M.
Teunissen, Charlotte E.
Kramer, Joel H.
Grinberg, Lea T.
Seeley, William W.
Rosen, Howie
Boeve, Bradley F.
Miller, Bruce L.
Rabinovici, Gil D.
Dage, Jeffrey L. http://orcid.org/0000-0002-2192-1699
Rojas, Julio C.
Boxer, Adam L. http://orcid.org/0000-0002-1215-5064
Article History
Received: 19 July 2019
Accepted: 10 January 2020
First Online: 2 March 2020
Competing interests
: E.H.T, R.L.J., A.W., A.S., P.W., L.I., V.B., Y.C., H.H., S.S., A.M.K., C.E.T., J.H.K., W.W.S., H.R., B.F.B. and B.L.M. declare no conflict of interest. J.L.D., X.C., N.K.P., D.C.A., S.S., C.D.E. and J.R.S. are employees of Eli Lilly and Company. H.Z. has served on scientific advisory boards for Roche Diagnostics, Wave, Samumed and CogRx, has given lectures in symposia sponsored by Alzecure and Biogen and is a cofounder of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg. K.B. served as a consultant or on advisory boards for Alector, Biogen, CogRx, Eli Lilly, MagQu, Novartis and Roche Diagnostics and is a cofounder of Brain Biomarker Solutions in Gothenburg AB, a GU Venture-based platform company at the University of Gothenburg, all unrelated to the work presented in this paper. L.T.G. receives research support from Avid Radiopharmaceuticals and Eli Lilly. She has received consulting fees from the Simon Foundation and Cura Sen. She serves as Associate Editor for Frontiers in Aging Neurosciences, Frontiers in Dementia and the Journal of Alzheimer Disease. G.D.R. receives research support from the National Institutes of Health (NIH), Alzheimer’s Association, American College of Radiology, Tau Research Consortium, Avid Radiopharmaceuticals, Eli Lilly, GE Healthcare and Life Molecular Imaging. He has served as a consultant for Eisai, Merck and Axon Neurosciences. He received speaking honoraria from GE Healthcare. He serves as Associate Editor for JAMA Neurology. J.C.R. is a Site Principal Investigator for clinical trials supported by Eli Lilly and receives support from NIH. A.L.B. receives research support from NIH, the Tau Research Consortium, the Association for Frontotemporal Degeneration, Bluefield Project to Cure Frontotemporal Dementia, Corticobasal Degeneration Solutions, the Alzheimer’s Drug Discovery Foundation and the Alzheimer’s Association. He has served as a consultant for Aeton, Abbvie, Alector, AGTC, Amgen, Arkuda, Arvinas, Asceneuron, Eisai, Ionis, Lundbeck, Novartis, Passage BIO, Sangamo, Samumed, Third Rock, Toyama and UCB, and received research support from Avid, Biogen, BMS, C2N, Cortice, Eisai, Eli Lilly, Forum, Genentech, Janssen, Novartis, Pfizer, Roche and TauRx.